Earnings call transcript: Atomo Diagnostics posts strong H2 2026 growth

Atomo Diagnostics reported a 41% increase in fiscal 2026 revenue to AUD 5.3 million, while underlying EBITDA improved by 39% to a loss of just over AUD 2 million. The company's shares remained unchanged at $0.018 following the earnings call, trading at $0.02 later in the day, near the lower end of its 52-week range. HIV product revenue grew 21% to AUD 2.8 million, while OEM revenue surged more than 200% to AUD 2.2 million.

Gross margin declined to 35% from 51% due to a shift in the sales mix and the absence of high-margin fees from the prior year. Cash stood at AUD 3.7 million, with no debt. The company attributes its growth to expanding sales across HIV and OEM products, better cost control, and moving closer to profitability.